Elevance Health Inc
ELV: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$791.00 | Wftsnhg | Wgpwlbgr |
Elevance Earnings: Mix Shift Boosts Bottom Line and 2024 Outlook Slightly
Narrow-moat Elevance delivered slightly higher first-quarter results than expected and mildly increased its 2024 guidance, despite continued medical membership losses from Medicaid eligibility redeterminations. Our near- and long-term forecasts have not changed materially, and we do not anticipate changing our $520 fair value estimate. Recent trades appear close to fair value.